Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Objectives: To review studies developing or validating a prognostic model for individual venous thromboembolism (VTE) recurrence risk following cessation of therapy for a first unprovoked VTE. Prediction of recurrence risk is crucial to informing patient prognosis and treatment decisions. The review aims to determine whether reliable prognostic models exist and, if not, what further research is needed within the field. Design: Bibliographic databases (including MEDLINE, EMBASE and the Cochrane Library) were searched using index terms relating to the clinical field and prognosis. Screening of titles, abstracts and subsequently full texts was conducted by 2 reviewers independently using predefined criteria. Quality assessment and critical appraisal of included full texts was based on an early version of the PROBAST (Prediction study Risk Of Bias Assessment Tool) for risk of bias and applicability in prognostic model studies. Setting: Studies in any setting were included. Primary and secondary outcome measures: The primary outcome for the review was the predictive accuracy of identified prognostic models in relation to VTE recurrence risk. Results: 3 unique prognostic models were identified including the HERDOO2 score, Vienna prediction model and DASH score. Quality assessment highlighted the Vienna, and DASH models were developed with generally strong methodology, but the HERDOO2 model had many methodological concerns. Further, all models were considered at least at moderate risk of bias, primarily due to the need for further external validation before use in practice. Conclusions: Although the Vienna model shows the most promise (based on strong development methodology, applicability and having some external validation), none of the models can be considered ready for use until further, external and robust validation is performed in new data. Any new models should consider the inclusion of predictors found to be consistently important in existing models (sex, site of index event, D-dimer), and take heed of several methodological issues identified through this review. PROSPERO registration number: CRD42013003494.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the systematic review of prognostic models 275 identified 3 scores: HERDOO2, Vienna, and DASH.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [275]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Multiple imputation using chained equations: Issues and guidance for practice
White, I. R., Royston, P., & Wood, A. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4067 · Cited by 9,792
A simulation study of the number of events per variable in logistic regression analysis
Peduzzi, P., Concato, J., Kemper, E., Holford, T. R., & Feinstein, A. R. (1996) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00236-3 · Cited by 9,655
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119 · cited 1×
“It is usual to treat an initial VTE for a minimum of 3 months; however, the optimum duration of therapy beyond this is unclear.(6) 7 Treatment with novel oral anticoagulants is a new alternative treatment to heparin and warfarin.”
BackgroundClinical Prediction Models: A Practical Approach to Development, Validation, and Updating
Steyerberg, E. W. (2019) · Statistics for Biology and Health · doi:10.1007/978-3-030-16399-0 · Cited by 3,281
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884
Self-citationPeduzzi, P., Concato, J., Feinstein, A. R., & Holford, T. R. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(95)00048-8 · Cited by 2,154
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. (2015) · BMC Medicine · doi:10.1186/s12916-014-0241-z · Cited by 1,927
Venous thrombosis: a multicausal disease
Rosendaal, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10266-0 · Cited by 1,576
Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research
Steyerberg, E. W., Moons, K. G. M., van der Windt, D. A., Hayden, J. A., Perel, P., Schroter, S., Riley, R. D., Hemingway, H., Altman, D. G., & for the PROGRESS Group (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001381 · Cited by 1,508 · cited 4×
“Even then the impact of the model on clinical decision-making and, crucially, patient outcomes should be evaluated through a randomised trial, ideally, or health economic modelling exercise.(11) 43 Any new models should try to build on the existing work, ensure external validation in multiple populations, transparency…”
BackgroundMethodInfluentialSelf-citation
Research works printed but not linked: 10
- 30. Rodger MA, Rodger M, Kovacs M Extended follow-up of the multi-center prospective cohort that derived the ‘men continue and HERDOO2’ clinical decision rule identifying low risk unprovoked patients. Journal of Thrombosis and Haemostasis 2011; Conference: 23rd Congress of the International Society on Thrombosis and Haemostasis 57th Annual SSC Meeting Kyoto Japan. Conference Start: 20110723 Conference End: 20110728. Conference Publication: (var.pagings): 39– 40.
- 31. Lazo-Langner A, Abdulrehman J, Taylor EJ The use of the REVERSE study clinical prediction rule for risk stratification after initial anticoagulation results in decreased recurrences in patients with idiopathic venous thromboembolism. Journal of Thrombosis and Haemostasis; Conference: 24th Congress of the International Society on Thrombosis and Haemostasis Amsterdam Netherlands. Conference Start: 20130629 Conference End: 20130704. Conference Publication: (varpagings)11 (pp 879), 201 2013(var.pagings): 879.
- 32. Marcucci M, Eichinger S, Iorio A External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database. Journal of Thrombosis and Haemostasis; Conference: 24th Congress of the International Society on Thrombosis and Haemostasis Amsterdam Netherlands. Conference Start: 20130629 Conference End: 20130704. Conference Publication: (varpagings)11 (pp 879-880) 2013(var.pagings): 879– 80.
- 33. Rodger M, Kovacs M, Le GG The REVERSE I and II studies: impact of using. Men continue and HERDOO2 clinical decision rule to guide anticoagulant therapy in patients with first unprovoked venous thromboembolism. Journal of Thrombosis and Haemostasis; Conference: 24th Congress of the International Society on Thrombosis and Haemostasis Amsterdam Netherlands. Conference Start: 20130629 Conference End: 20130704. Conference Publication: (varpagings)11 (pp 114), 201 2013(var.pagings): 114.
- 35. Raskob GE, Anthonie LWA, Prins MH Risk assessment for recurrent venous thromboembolism (VTE) after 6-14 months of anticoagulant treatment. Journal of Thrombosis and Haemostasis 2011; Conference: 23rd Congress of the International Society on Thrombosis and Haemostasis 57th Annual SSC Meeting Kyoto Japan. Conference Start: 20110723 Conference End: 20110728. Conference Publication: (var.pagings): 857– 8.
- 37. Tosetto A, Iorio A, Marcucci M Clinical prediction of VTE recurrence in patients with previous unprovoked venous thromboembolism. Results from an individual-level meta-analysis. Pathophysiology of Haemostasis and Thrombosis 2010; Conference: 21st International Congress on Thrombosis—The Start of a New Era Antithrombotic Agents Milan Italy. Conference Start: 20100706 Conference End: 20100709. Conference Publication: (var.pagings): A29.
- 38. Tosetto A, Lorio A, Marcucci M Clinical prediction guide to predict thrombosis recurrence after a first unprovoked venous thromboembolism. Journal of Thrombosis and Haemostasis 2009; Conference: 22nd Congress of the International Society of Thrombosis and Haemostasis Boston, MA United States. Conference Start: 20090711 Conference End: 20090716. Conference Publication: (var.pagings): 266.
- 41. Eichinger S, Heinze G, Kyrle PA D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. Vasa—Journal of Vascular Diseases; Conference: 16th Tri-Country Congress of the Austrian, German and Swiss Society of Angiology 2013 Graz Austria. Conference Start: 20130915 Conference End: 20130918. Conference Publication: (varpagings) 42 (pp 36), 20 2014 (var.pagings):36-Journal. 10.1161/JAHA.113.000467 PMC3959721 24385451 · DOI
- 42. Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation (Structured abstract). 2016. http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013001066/frame.html (accessed 29 Apr 2016).
- 44. Eichinger S, Heinze G, Kyrle PA D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc 2014; 3: e000467 10.1161/JAHA.113.000467 24385451 PMC3959721 · DOI
Cited by
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Calculating the sample size required for developing a clinical prediction model
Riley, R. D., Ensor, J., Snell, K. I. E., Harrell, F. E., Martin, G. P., Reitsma, J. B., Moons, K. G. M., Collins, G., & van Smeden, M. (2020) · BMJ · doi:10.1136/bmj.m441 · Cited by 2,917
Self-citationKonstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01647-2019 · Cited by 1,619
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Kakkos, S. K., Gohel, M., Baekgaard, N., Bauersachs, R., Bellmunt-Montoya, S., Black, S. A., ten Cate-Hoek, A. J., Elalamy, I., Enzmann, F. K., Geroulakos, G., et al. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2020.09.023 · Cited by 743
D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applications
Favresse, J., Lippi, G., Roy, P.-M., Chatelain, B., Jacqmin, H., ten Cate, H., & Mullier, F. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1529734 · Cited by 212
Stability of clinical prediction models developed using statistical or machine learning methods
Riley, R. D., & Collins, G. S. (2023) · Biometrical Journal · doi:10.1002/bimj.202200302 · Cited by 211
“For example, for recurrence of venous thromboembolism (Ensor et al., 2016), predicted risks between about 0.03 and 0.20 have been suggested to warrant clinical action, such as remaining on anticoagulation therapy.”
BackgroundInfluentialSelf-citationThrombophilia testing: A British Society for Haematology guideline
Arachchillage, D. J., Mackillop, L. H., Chandratheva, A., Motawani, J., MacCallum, P., & Laffan, M. (2022) · British Journal of Haematology · doi:10.1111/bjh.18239 · Cited by 196
Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus
Seliverstov, E. I., Lobastov, K. V., Ilyukhin, Е. А., Apkhanova, T. V., Akhmetzyanov, R. V., Akhtyamov, I. F., Barinov, V., Bakhmetiev, A. S., Belov, M. V., Александрович, Б. С., et al. (2023) · Journal of Venous Disorders · doi:10.17116/flebo202317031152 · Cited by 121
Hodgson, L. E., Sarnowski, A., Roderick, P. J., Dimitrov, B. D., Venn, R. M., & Forni, L. G. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016591 · Cited by 100
Thrombophilia screening revisited: an issue of personalized medicine
Colucci, G., & Tsakiris, D. Α. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02090-y · Cited by 97
External validation of the DASH prediction rule: a retrospective cohort study
Tosetto, A., Testa, S., Martinelli, I., Poli, D., Cosmi, B., Lodigiani, C., Ageno, W., Stefano, V. D., Falanga, A., Nichele, I., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13781 · Cited by 90
Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study
Albertsen, I. E., Nielsen, P. B., Søgaard, M., Goldhaber, S. Z., Overvad, T. F., Rasmussen, L. H., & Larsen, T. B. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.04.042 · Cited by 72
de Winter, M. A., van Es, N., Buller, H. R., Visseren, F. L. J., & Nijkeuter, M. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.031 · Cited by 68
Timp, J. F., Brækkan, S. K., Lijfering, W. M., Vlieg, A. V. H., Hansen, J., Rosendaal, F. R., le Cessie, S., & Cannegieter, S. C. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002883 · Cited by 61
Chiasakul, T., Lam, B. D., McNichol, M. C., Robertson, W. E., Rosovsky, R. P. G., Lake, L. L., Vlachos, I. S., Adamski, A., Reyes, N., Abe, K., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14110 · Cited by 57
D-dimer testing: A narrative review
Wauthier, L., Favresse, J., Hardy, M. J., Douxfils, J., Gal, G. L., Roy, P., van Es, N., Ay, C., Cate, H. T., Lecompte, T., et al. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.02.006 · Cited by 58
Kunutsor, S. K., Whitehouse, M. R., Blom, A. W., & Beswick, A. D. (2017) · Epidemiology and Infection · doi:10.1017/s0950268817000486 · Cited by 59
Artificial neural networks for prediction of recurrent venous thromboembolism
Martins, T. D., Annichino‐Bizzacchi, J. M., Romano, A. V. C., & Filho, R. M. (2020) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2020.104221 · Cited by 47
Wingbermühle, R. W., van Trijffel, E., Nelissen, P. M., Koes, B. W., & Verhagen, A. P. (2017) · Journal of physiotherapy · doi:10.1016/j.jphys.2017.11.013 · Cited by 48
Bridge, J., Blakey, J., & Bonnett, L. J. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-0913-7 · Cited by 40
Ensor, J., Riley, R. D., Jowett, S., Monahan, M., Snell, K. I., Bayliss, S., Moore, D., Fitzmaurice, D., & on behalf of the PIT-STOP collaborative group (2016) · Health Technology Assessment · doi:10.3310/hta20120 · Cited by 40
Self-citationPrincipal Component Analysis on Recurrent Venous Thromboembolism
Martins, T. D., Annichino‐Bizzacchi, J. M., Romano, A. V. C., & Filho, R. M. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619895323 · Cited by 39
Панченко, Е. П., Balahonova, T. V., Danilov, N. M., Komarov, A. L., Станиславовна, К. Е., Saidova, M. A., Shakhmatova, O. O., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-1-44-77 · Cited by 39
Ogero, M. O., Sarguta, R. J., Malla, L., Aluvaala, J., Agweyu, A., English, M., Onyango, N. O., & Akech, S. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-035045 · Cited by 37
Systematic review of clinical prediction models to support the diagnosis of asthma in primary care
Daines, L., McLean, S., Buelo, A., Lewis, S. C., Sheikh, A., & Pinnock, H. (2019) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-019-0132-z · Cited by 38
Minno, M. N. D. D., Calcaterra, I. L., Papa, A., Lupoli, R., Minno, A. D., Maniscalco, M., & Ambrosino, P. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.04.004 · Cited by 29
Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities
Stevens, H., Peter, K., Tran, H. A., & McFadyen, J. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051582 · Cited by 28
Eppenberger, D., Nilius, H., Anagnostelis, B., Huber, C. A., & Nagler, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.883986 · Cited by 28
Systematic review of risk prediction scores for venous thromboembolism following joint replacement
Kunutsor, S. K., Beswick, A. D., Whitehouse, M. R., & Blom, A. W. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.06.024 · Cited by 22
“To ensure that risk prediction scores are reliable for the intended patients, standard consistent definitions need to be employed.[27] Second, of the three studies that reported development of a risk prediction model, none was developed in a cohort recruited for this sole purpose, thereby introducing an inherent selec…”
BackgroundMethodInfluentialCooray, S. D., Wijeyaratne, L. A., Soldatos, G., Allotey, J., Boyle, J. A., & Teede, H. J. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17093048 · Cited by 27
Poénou, G., Toledano, E., Helfer, H., Plaisance, L., Happe, F., Versini, E., Diab, N., Djennaoui, S., & Mahé, I. (2022) · Cancers · doi:10.3390/cancers14081937 · Cited by 22
Zhang, H., Shao, J., Chen, D., Zou, P., Cui, N., Tang, L., Wang, D., & Ye, Z. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s283949 · Cited by 19
Nagler, M., van Kuijk, S. M. J., Cate, H. T., Prins, M. H., & ten Cate‐Hoek, A. J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.655226 · Cited by 17
Nieto, T., Tomlinson, C. L., Dretzke, J., Bayliss, S. E., Price, M. J., Dilworth, M., Beggs, A. D., & Tucker, O. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020427 · Cited by 17
Self-citationPallazola, V. A., Kapoor, R. K., Kapoor, K., McEvoy, J. W., Blumenthal, R. S., & Gluckman, T. J. (2019) · Vascular Medicine · doi:10.1177/1358863x18819816 · Cited by 14
Update on diagnosis and anticoagulant therapy for venous thromboembolism
Stevens, H., & Tran, H. A. (2018) · Internal Medicine Journal · doi:10.1111/imj.14063 · Cited by 13
Scheres, L. J. J., Lijfering, W. M., Middeldorp, S., Cheung, Y. W., Barco, S., Cannegieter, S. C., & Coppens, M. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12142 · Cited by 13
Agrawal, V., & Kim, E. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1111-2 · Cited by 15
JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis
Tamura, Y., Kusunose, K., Yamashita, Y., Akagi, T., Atsukawa, M., Fukumoto, Y., Goda, A., Goto, S., Hatano, M., Ikeda, M., et al. (2026) · Circulation Journal · doi:10.1253/circj.cj-25-1144 · Cited by 14
Risk Scores in Venous Thromboembolism Guidelines of ESC, ACCP, and ASH: An Updated Review
Xiong, W. G., Cheng, Y., & Zhao, Y. (2024) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296241263856 · Cited by 12
Evans, V. J., Lawrence, M. J., Whitley, J., Johns, C., Pillai, S., Hawkins, K. M., Power, K., Morris, K., Williams, P. R., & Evans, P. A. (2021) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-201030 · Cited by 12
“The GP technique has been previously validated for use with blood in several studies [2, 5, 6].”
Circulating microRNAs predict recurrence and death following venous thromboembolism
ten Cate, V., Rapp, S., Schulz, A., Robles, A. P., Jurk, K., Koeck, T., Espinola–Klein, C., Halank, M., Seyfarth, H., Beutel, M. E., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.07.010 · Cited by 11
Risk factors for venous thromboembolism (VTE) recurrences in Thai patients without cancer
Satpanich, P., & Rojnuckarin, P. (2018) · Hematology · doi:10.1080/10245332.2018.1535535 · Cited by 12
State of play and future direction with NOACs: An expert consensus
Cohen, A. T., Lip, G. Y. H., Caterina, R. D., Heidbüchel, H., Zamorano, J. L., Agnelli, G., Verheugt, F. W. A., & Camm, A. J. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.04.001 · Cited by 11
Outpatient treatment of emergency department patients diagnosed with venous thromboembolism
Stubblefield, W. B., & Kline, J. A. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1916299 · Cited by 10
Sex, gender and venous thromboembolism: do we care enough?
Faioni, E. M., Zighetti, M. L., & Vozzo, N. (2018) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000773 · Cited by 10
Bannoud, M. A., Martins, T. D., Montalvão, S. A. D. L., Annichino‐Bizzacchi, J. M., Filho, R. M., & Maciel, M. R. W. (2025) · Neural Computing and Applications · doi:10.1007/s00521-025-11070-3 · Cited by 8
An update on the pharmaceutical management of thrombosis
Cosmi, B. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241233 · Cited by 8
Marín-Romero, S., Elías-Hernández, T., Asensio-Cruz, M. I., Ortega-Rivera, R., Morillo-Guerrero, R., Toral, J., Montero, E., Sánchez‐López, V., Arellano, E., Sánchez-Díaz, J. M., et al. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2019.10.001 · Cited by 8
Managing challenging patients with venous thromboembolism: a practical, case-based approach
Douketis, J. D., Ageno, W., Carrier, M., & Kearon, C. (2017) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3879 · Cited by 7
Marín-Romero, S., Elías-Hernández, T., Asensio-Cruz, M. I., Ortega-Rivera, R., Morillo-Guerrero, R., Toral, J., Montero, E., Sánchez‐López, V., Arellano, E., Sánchez-Díaz, J. M., et al. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2019.03.025 · Cited by 7
Yamashita, Y., Amano, H., Morimoto, T., Kadota, K., Hata, R., Matsushita, K., Osakada, K., Sano, A., Takase, T., Hiramori, S., et al. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02520-5 · Cited by 7
Systematic review of methods used in prediction models with recurrent event data
Watson, V., Smith, C. T., & Bonnett, L. J. (2024) · Diagnostic and Prognostic Research · doi:10.1186/s41512-024-00173-5 · Cited by 6
“Similarly, information about the models’ calibration performance, which assesses the agreement between the observed probability to the predicted probability of risk, was extracted where available [2, 3].”
BackgroundScoring Systems for Estimating the Risk of Recurrent Venous Thromboembolism
Nichele, I., & Tosetto, A. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1602662 · Cited by 7
Sundquist, K., Ahmad, A., Svensson, P. J., Zöller, B., Sundquist, J., & Memon, A. A. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1662-x · Cited by 6
Ahmad, A., Memon, A. A., Sundquist, J., Svensson, P. J., Zöller, B., & Sundquist, K. (2018) · Gene · doi:10.1016/j.gene.2018.01.013 · Cited by 7
“after anticoagulation therapy stops (Kyrle et al., 2010; Ensor et al., 2016).”
Incidence of Recurrent Venous Thromboembolism in a Population-Based Cohort
Ruthström, T., Hägg, L., Johansson, L. Å., Lind, M. M., & Johansson, M. (2024) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296241293337 · Cited by 5
“As male sex is included as a predictor for increased risk of VTE recurrence in many prediction models, 17 – 19 we fi nd it important to underline that male sex is not associated with increased risk of recurrence in all populations.”
BackgroundInitial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives
Ageno, W., & Donadini, M. P. (2018) · Hämostaseologie · doi:10.1055/s-0038-1641605 · Cited by 4
New evidence in diagnosis of pulmonary embolism during pregnancy
Viau-Lapointe, J., & Arsenault, M.-P. (2019) · Obstetric Medicine · doi:10.1177/1753495x19875589 · Cited by 4
Minimizing recurrent venous thromboembolism
Bikdeli, B., Krumholz, H. M., & Hines, H. H. (2019) · BMJ · doi:10.1136/bmj.l4686 · Cited by 4
Timp, J. F., Brækkan, S. K., Lijfering, W. M., Vlieg, A. V. H., Hansen, J., Rosendaal, F. R., le Cessie, S., & Cannegieter, S. C. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003612 · Cited by 4
Bosio, G., Destrempes, F., Cardinal, M. R., & Cloutier, G. (2024) · Journal of Ultrasound in Medicine · doi:10.1002/jum.16411 · Cited by 3
Leung, P. C., Ho, P. W., & Lim, H. Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041509 · Cited by 3
“For the risk of recurrence in unprovoked VTE, the HERDOO2, Vienna and DASH scores are largely unvalidated in men, cancer patients and those with high-risk thrombophilia [122].”
Management of Acute Pulmonary Embolism: A Review
Bhave, A. A., Dumra, H. S., & Bansal, S. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0737 · Cited by 3
Extended oral anticoagulation after incident venous thromboembolism – a paradigm shift?
Albertsen, I. E., Piazza, G., Søgaard, M., Nielsen, P. B., & Larsen, T. B. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1755260 · Cited by 3
Brazilek, R., & Cleland, H. J. (2021) · European Burn Journal · doi:10.3390/ebj2030006 · Cited by 3
Albertsen, I. E., Konstantinides, S., Piazza, G., Goldhaber, S. Z., Larsen, T. B., Søgaard, M., & Nielsen, P. B. (2022) · TH Open · doi:10.1055/a-1949-9404 · Cited by 4
Mrozińska, S., Cieślik, J., Broniatowska, E., & Undas, A. (2018) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4317 · Cited by 2
Ferrari, É., Fourrier, E., Asarisi, F., Heme, N., Redjimi, N., Berkane, N., Labbaoui, M., Breittmayer, J. P., Bun, S. S., Moceri, P., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050910 · Cited by 4
Kruger, P. C., & Eikelboom, J. W. (2017) · Annals of Internal Medicine · doi:10.7326/acpjc-2017-167-6-033 · Cited by 2
CLINICAL DISCUSSION OF A PATIENT WITH RECURRENT VENOUS THROMBOEMBOLIC COMPLICATIONS
Komarov, A. L. (2017) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2017-2-79-94 · Cited by 1
Should anti-vitamin K be started on the first day in non-high risk pulmonary embolism?
Koracevic, G. P., & Ilić, D. (2019) · Vojnosanitetski pregled · doi:10.2298/vsp170121001k · Cited by 1
Limperger, V., Torge, A., Kiesau, B., Länger, F. P., Kenet, G., Mesters, R. M., Juhl, D., Stoll, M., Shneyder, M., Kowalski, D., et al. (2022) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2022.102651 · Cited by 1
Karathanos, C., Spanos, K. T., & Giannoukas, A. D. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.007 · Cited by 1
Liem, T. K., & Almeida, J. I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-51139-1.00012-7 · Cited by 1
Roy, P. (2016) · European Respiratory Journal · doi:10.1183/13993003.01646-2016
Planquette, B. (2016) · theses.fr (ABES) · doi:10.70675/dc546a1azf2f5z4074z99edz4020d11e698a · Cited by 3
Current Tendencies in the Prevention of Recurrent Venous Thromboembolism
Ilyukhin, Е. А., & Zolotukhin, I. A. (2017) · Journal of Venous Disorders · doi:10.17116/flebo201711283-90 · Cited by 1
“Однако ни одна из них, в том числе и наиболее удачная Венская, не может считаться готовой для дальнейшего использования в клинической практике из-за ряда ограничений и необходимости проведения дальнейших дополнительных исследований [21].”
Mój pacjent leczony sulodeksydem — kiedy i dlaczego stosuję?
Gorczyca−Michta, I., & Wożakowska−Kapłon, B. (2017) · Folia Cardiologica · doi:10.5603/fc.2017.0109 · Cited by 1
Ahmad, A., Sundquist, K., Svensson, P. J., Sundquist, J., Zöller, B., & Memon, A. A. (2018) · Gene Reports · doi:10.1016/j.genrep.2018.09.007
A vénás tromboembólia kezelése ma, 10 évvel az első direkt orális antikoaguláns megjelenése után
Vértes, A. (2019) · Cardiologia Hungarica · doi:10.26430/chungarica.2019.49.1.51
Thrombophilieabklärung im Hinblick auf östrogenhaltige Kontrazeptiva und Hormonersatztherapie
Pollak, M., & Nagler, M. (2019) · Gynäkologische Endokrinologie · doi:10.1007/s10304-019-0262-y · Cited by 1
de Winter, M. A. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1132
Developing Real-World Patient Pathways in Acute Pulmonary Embolism
Agnew, S. (2016) · EMJ Cardiology · doi:10.33590/emjcardiol/10310296
Impact de l’épicatéchine sur l’hémostase et la structure du caillot de fibrine
Sinegre, T. (2021) · theses.fr (ABES) · doi:10.70675/952bddc2z91abz4134zb35bze03dcbbb92fe · Cited by 1
Kiran, D. R., & Jothieswari, D. D. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.12s.33
Fengfei, Y. A. N., Han, S., Peng, C., Yang, B., & Wang, H. (2026) · Archives of Pharmacal Research · doi:10.1007/s12272-026-01636-7
“Existing recurrent VTE risk models and clinical decision rules, such as the Vienna prediction model and HERDOO2, have been developed and evaluated in clinically defined cohorts (Eich-inger et al. 2010; Ensor et al. 2016; Rodger et al. 2017; Ste-vens et al. 2020).”
Metadata
- Authors
- Ensor, J., Riley, R. D., Moore, D., Snell, K. I. E., Bayliss, S., & Fitzmaurice, D.
- Affiliations
- Keele University (GB)
- University of Birmingham (GB)
- Corresponding author
- Ensor, Joie
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2016-05
- Volume
- 6
- Issue
- 5
- Pages
- e011190
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC4861103
- OpenAlex
- W2346047977
- Cited by
- 84
- References
- 53
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 9 · 2020: 11 · 2019: 15 · 2018: 16 · 2017: 10 · 2016: 4
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMJ Open (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Health Technology Assessment Programme (10/94/02)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- venous thromboembolism, VTE recurrence, prognostic model, recurrence risk prediction, DASH score, risk of bias, external validation, D-dimer, sex
- MeSH terms
- Anticoagulants, Humans, Prognosis, Recurrence, Risk Factors, Decision Support Systems, Clinical, Venous Thromboembolism, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.